Roivant Sciences Ltd. — Director's Dealing 2019

Dec 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2019-12-18

Reporting Person: Roivant Sciences Ltd. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-18	Common Stock, $0.0001 par value per share	J	36919967	$10.00	Acquired	37404967	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-18	Series A Preferred Stock, $0.0001 par value per share	$	J	10000	Acquired		Common Stock, $0.0001 par value per share (10000)	Direct

Footnotes

F1: The transaction was pursuant to a Share Exchange Agreement, dated as of September 29, 2019, where Roivant received 36,917,339 shares of Common Stock in consideration for its equity securities of Immunovant Sciences Ltd., as well as 10,000 shares of Series A Preferred Stock

F2: The price reported in Column 4 is the deemed value of the shares in the Share Exchange Agreement

F3: Each share of Series A Preferred Stock is convertible into common stock on a one-for-one basis into the number of shares of common stock shown in column 7 at any time at the holder's election. The Series A Preferred Stock has no expiration date.

F4: The price reported in Column 8 is the deemed value of the shares in the Share Exchange Agreement